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Q fever is a widespread zoonosis caused by Coxiella burnetii. Diagnosis of Q fever is usually based on
serological testing of patient serum. The diagnostic antigen of test kits is formalin-fixed phase I and phase II
organisms of the Nine Mile reference strain. Deficiencies of this antigen include (i) potential for cross-
reactivity with other pathogens; (ii) an inability to distinguish between C. burnetii strains; and (iii) a need to
propagate and purify C. burnetii, a difficult and potentially hazardous process. Consequently, there is a need
for sensitive and specific serodiagnostic tests utilizing defined antigens, such as recombinant C. burnetii
protein(s). Here we describe the use of a C. burnetii protein microarray to comprehensively identify immuno-
dominant antigens recognized by antibody in the context of human C. burnetii infection or vaccination.
Transcriptionally active PCR products corresponding to 1,988 C. burnetii open reading frames (ORFs) were
generated. Full-length proteins were successfully synthesized from 75% of the ORFs by using an Escherichia
coli-based in vitro transcription and translation system (IVTT). Nitrocellulose microarrays were spotted with
crude IVTT lysates and probed with sera from acute Q fever patients and individuals vaccinated with Q-Vax.
Immune sera strongly reacted with approximately 50 C. burnetii proteins, including previously identified
immunogens, an ankyrin repeat-domain containing protein, and multiple hypothetical proteins. Recombinant
protein corresponding to selected array-reactive antigens was generated, and the immunoreactivity was con-
firmed by enzyme-linked immunosorbent assay. This sensitive and high-throughput method for identifying
immunoreactive C. burnetii proteins will aid in the development of Q fever serodiagnostic tests based on
recombinant antigen.
Coxiella burnetii is a gram-negative obligate intracellular
bacterium and the etiological agent of the zoonosis Q
(“query”) fever. Human populations most at risk for infection
are those routinely exposed to infected animals and their prod-
ucts. The organism has a diverse animal reservoir that includes
domestic livestock such as dairy cattle, goats, and sheep.
Chronically infected dairy cattle shed C. burnetii in milk and
other secretions, and the products of livestock parturition can
deposit tremendous numbers of the organisms into the envi-
ronment. The insidious nature of C. burnetii is further exacer-
bated by the organism’s aerosol route of infection, low infec-
tious dose, and pronounced extracellular stability. Q fever
most commonly manifests as a self-limiting but debilitating
influenza-like illness that includes signs and/or symptoms of
prolonged high fever, headache, and malaise. Chronic infec-
tion can occur, normally in predisposed individuals, that typi-
cally presents as a life-threatening endocarditis (reviewed in
reference 17).
Two advancements that would aid in control of Q fever are (i)
a specific and sensitive serodiagnostic test based on recombinant
antigen and (ii) an efficacious and safe vaccine that does not
require prevaccination skin testing. Human Q fever is currently
diagnosed by clinical presentation and supporting serological re-
sponses against fixed, whole-cell phase I and phase II forms of the
C. burnetii Nine Mile reference strain. Platforms for serological
testing include immunofluorescence, complement fixation, en-
zyme-linked immunosorbent assay (ELISA) and microagglutina-
tion (21). Unfortunately, the complex nature of the whole-cell
antigen results in lack of uniformity and specificity in test results.
There is currently not a Food and Drug Administration-approved
Q fever vaccine for use in the United States, although a killed-
cellular vaccine (Q-Vax) is licensed in Australia (15). Q-Vax,
along with other investigational vaccines based on formalin-inac-
tivated organisms, are highly efficacious in prevention of Q fever
by inducing both robust humoral and cell-mediated immune re-
sponses to C. burnetii antigens (33). However, these vaccines can
cause severe local and occasionally systemic reactions in individ-
uals previously sensitized to C. burnetii. Thus, skin testing for
preexisting immunity against C. burnetii is required prior to vac-
cination (16). Since both current commercial serological tests and
vaccines rely on intact organisms, a biosafety level 3 laboratory is
required for antigen production.
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With the ready availability of pathogen genome sequences,
reverse approaches to vaccine and diagnostic antigen discovery
are feasible (18). Pathogen antigen screens using E. coli-ex-
pressed recombinant protein have used bioinformatic tools to
prioritize proteins for screening. Reductive strategies are used
to remove housekeeping proteins and other proteins present in
nonpathogens, while retaining proteins predicted to interact
with the host immune system, such as known or suspected
virulence-associated proteins that are surface exposed or se-
creted (11). For example, by screening 156 bioinformatically
selected Chlamydia trachomatis recombinant proteins with sera
from urogenitally infected patients, novel antigens were re-
vealed, some of which are secreted during the course of infec-
tion (24). Unbiased genome-scale antigen discovery using E.
coli-expressed antigen has also been performed. A near-total
proteome screen using purified recombinant protein was con-
ducted with Treponema pallidum, wherein ca. 85% of the or-
ganism’s predicted proteins were tested for serological reactiv-
ity in a 96-well plate platform (4). That study identified novel
antigens that are differentially recognized by sera from patients
in primary, secondary, and latent disease stages of syphilis.
Although informative, genome-scale antigen discovery using
purified recombinant protein is labor intensive and E. coli
expression of heterologous proteins can be problematic due to
toxicity and insolubility. To circumvent these problems and to
provide a more high-throughput platform, protein microarrays
utilizing recombinant protein expressed by in vitro transcrip-
tion and translation (IVTT) have been developed (2, 7, 8). In
this procedure, whole-genome DNA libraries consisting of ei-
ther individual plasmid-cloned genes or gene-specific tran-
scriptionally active PCR (TAP) products are used as templates
in IVTT reactions (7, 20). Nanoliter amounts of crude IVTT
lysates containing synthesized protein are then spotted onto
nitrocellulose-coated glass slides in a microarray format and
screened for antibody reactivity using a fluorescence scanner
(7). Davies et al. (7, 8) were first to describe an unbiased
“immunoproteome” serological screen using IVTT synthesized
protein. Using high-throughput methods of PCR amplification
and in vivo recombinational cloning into a T7 promoter ex-
pression plasmid, these researchers identified 14 proteins
within the vaccinia proteome that strongly react with vaccinia
virus immun.globulin. This technology was later used to iden-
tify 48 and 103 immunodominant antigens of Francisella tula-
rensis and Borrelia burgdorferi, respectively, from 80% of
these pathogen’s predicted proteomes (2, 10).
A more thorough understanding of the humoral response to
C. burnetii infection is necessary for development of a new
generation of Q fever diagnostics and vaccines based on re-
combinant antigen. To this end, we developed a C. burnetii
protein microarray to comprehensively identify immunodomi-
nant antigens recognized in the context of C. burnetii infection
or vaccination. A subset of these immunodominant antigens
was expressed as recombinant proteins, purified, and examined
for reactivity in a standardized ELISA format to correlate the
predictive ability of the array-identified proteins to serve as
defined antigen diagnostic reagents.
MATERIALS AND METHODS
Organism cultivation and chromosomal DNA isolation. The C. burnetii Nine
Mile isolate (RSA493) in phase I was used in the present study. Organisms were
propagated in African green monkey kidney (Vero) fibroblasts (CCL-81; Amer-
ican Type Culture Collection) grown in RPMI medium (Invitrogen, Carlsbad,
CA) supplemented with 2% fetal bovine serum. Organisms were purified by
Renografin density gradient centrifugation as previously described (5, 23). Total
genomic DNA was isolated directly from purified C. burnetii using an UltraClean
microbial DNA isolation kit (MoBio Laboratories, Inc., Carlsbad, CA). An
additional heating step (85°C for 30 min) was added before physical disruption
of the bacterial cells. All DNA was resuspended in distilled H2O and frozen at
20°C.
Generation of TAP products. TAP products were generated by using a mod-
ification of the Roche rapid translation system (RTS) E. coli linear template
generation set, the His6-Tag system (Roche Applied Science, Indianapolis, IN).
This system generates TAP products compatible with Roche’s RTS. The 5 and
3 gene-specific primers for first-round PCR were optimally designed by Sigma-
Genosys (St. Louis, MO) to specifically amplify each C. burnetii ORF. Up to five
codons were removed from the 5 and/or the 3 end of some ORF sequences to
allow specific amplification of similar genes (e.g., paralog gene families). The 5
end of each 5 primer also contains the sequence CACCATGGGCGGC, which
encodes tandem glycine codons (GGC), an ATG start codon, and the sequence
CACC to allow potential directional TOPO cloning (Invitrogen) for downstream
applications. The GGC codons were added to extend the length of common
sequence on 5 primers to allow annealing of primers for second-round PCR.
The 5 end of each 3 primer contains the sequence TCCAGCAATAGTTGG
GTTAAG, which encodes the epitope tag LNPTIAG. This peptide sequence
constitutes an immunodominant epitope of the C. trachomatis major outer mem-
brane protein and reacts with the monoclonal antibody L2I-10 (1). PCR products
of C. burnetii ORFs were generated by using 12 pmol of ORF-specific primers,
20 ng of C. burnetii genomic DNA, and Pfu DNA polymerase (Stratagene, La
Jolla, CA). Reactions were conducted in 96-well plates, and the resulting PCR
products were analyzed on a 0.8% agarose gel for the correct size. Aliquots of
both positive and negative PCRs were transferred by using a multichannel pi-
petter to new 96-well plates for second-round PCR. Complementary second-
round primers were used that incorporate unique overlap regions onto amplicon
ends to allow subsequent annealing of DNA fragments encoding T7 regulatory
elements and a C-terminal His6 tag. Aliquots of second PCRs were transferred
by using a multichannel pipetter to new 96-well plates for third-round PCR.
Regulatory element and His6 tag-encoding DNA fragments were added to wells
and incorporated in the final TAP product by a third round of PCR using
complementary primers. Second- and third-round PCR were conducted using
Accuprime Pfx DNA polymerase (Invitrogen) and 2 l of the previous round
PCR as a template. Final PCR products were purified by using a Roche High-
Pure 96 UF cleanup kit to remove nucleotides and primer dimers. TAP products
were analyzed on a 0.8% agarose gel for the correct size, and aliquots of all final
PCR products (both positive and negative for TAP product) were used in sub-
sequent IVTT reactions. A schematic of the TAP product synthesis is shown in
Fig. 1.
Generation of plasmid expression library. A revised version of a previously
published high-throughput recombination cloning method (7) was used to gen-
erate plasmids expressing a subset of C. burnetii antigens. In this revised method,
recombination was accomplished in vitro using the In-Fusion recombinase en-
zyme from Clontech. Custom PCR primers comprising 20 bp of gene-specific
sequence with 33 bp of “adapter” sequences were used in PCRs with C. burnetii
genomic DNA as a template. The adapter sequences, which become incorpo-
rated into the termini flanking the amplified gene, were homologous to the
cloning site of the linearized T7 expression vector pXT7 (7). A total of 40 ng of
PCR-generated linear vector was mixed with 10 to 50 ng of PCR-generated ORF
fragment (molar ratio, 1:1; vector, 1-kb ORF fragment) and 0.1 U of In-Fusion
enzyme (In-Fusion CF liquid PCR cloning kit; Clontech, Mountain View, CA) in
a total volume of 10 l. The mixture was incubated at 25°C for 30 min. For
transformation, 2 l of this mixture was added to 10 l of competent E. coli
DH5 cells. The mixture was incubated on ice for 45 min, heat shocked at 42°C
for 1 min, and then chilled on ice for 1 min. Transformed cells were mixed with
250 l of super optimal catabolizer medium (2% tryptone, 0.55% yeast extract,
10 mM NaCl, 10 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose),
incubated at 37°C for 1 h, and then diluted into 3 ml of LB medium supple-
mented with 50 g of kanamycin per ml. Cultures were incubated overnight with
shaking. Plasmids were isolated and purified from cultures without colony selec-
tion. We have found that this method using In-Fusion can reduce the amount of
linear vector and the amount of ORF PCR product needed for transformation
and greatly reduce the background level of empty vector in the plasmid prepa-
ration. It also enables shorter “adapter” sequences to be used, which reduces the
cost of the primers.
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IVTT expression of C. burnetii proteins. To produce IVTT protein from ex-
pression plasmids or TAP fragments, 10 l of DNA template was added to
individual wells of a 96-well Roche RTS 100 E. coli HY kit. IVTT reactions were
incubated for 8 h at 30°C with shaking (600 rpm) in a Roche RTS Proteomaster.
Samples were analyzed for the presence of C-terminal His6-tagged protein by dot
immunoblotting. Briefly, 3 l of each IVTT reaction was spotted onto a nitro-
cellulose membrane (Bio-Rad, Hercules, CA), which was blocked for 1 h in
PBST (10 mM sodium phosphate, 150 mM sodium chloride [pH 7.4], and 0.1%
Tween 20) containing 5% nonfat dry milk. One microgram of Penta-His mouse
monoclonal antibody (Qiagen, Valencia, CA) was then added, and the mem-
brane was incubated for 1 h with rocking. The membrane was washed three times
in PBST and then probed for 1 h with a peroxidase-conjugated anti-mouse
immunoglobulin G (IgG) secondary antibody diluted 1:5,000 in PBST. Bound
antibodies were detected by chemiluminescence using Supersignal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL) and Hyperfilm ECL (Am-
ersham, Piscataway, NJ).
Human sera. Serum samples from acute and chronic Q fever patients, Q-Vax
vaccinees, and naive individuals are part of an archived Australian serum bank
and were obtained from B. Marmion. Additional naive serum samples were
obtained from donors at the University of California–Irvine. Seroreactivity (IgG)
of serum samples against C. burnetii was determined by using an indirect fluo-
rescent antibody (IFA) kit (Focus Diagnostic, Cypress, CA) according to the
manufacturer’s instructions. Fifty-five acute Q fever patient sera collected be-
tween 38 and 172 days after the onset of clinical symptom were confirmed as
having phase II IgG IFA titers ranging from 1:160 to 1:5,120. Five chronic Q
fever endocarditis patient sera had both phase I and phase II IFA IgG titers
ranging from 160 to 1,280 and from 640 to 5,120, respectively. Thirty-two serum
samples from naive individuals were confirmed as IFA negative. Human serum
samples were used according to Institutional Review Board protocol 2003-0419
(J. E. Samuel).
Microarray detection of immunoreactive C. burnetii antigens. Portions (10 l)
of 0.125% Tween 20 were mixed with 15 l of each IVTT reaction (both His
tag-positive and -negative reactions) to give a final concentration of 0.05%
Tween 20. Then, 15-l portions of IVTT reaction-Tween mixtures were then
transferred to 384-well plates that were centrifuged at 1,600  g to pellet any
precipitated material. The supernatant was printed without further purification
onto nitrocellulose-coated FAST glass slides (Schleicher & Schuell, Keene, NH)
by using an OmniGrid 100 microarray printer (Genomic Solutions, Ann Arbor,
MI). Protein microarray chip printing was conducted by Douglas Molina at
Antigen Discovery, Inc., Irvine, CA. Prior to use with arrays, human sera (1:200
dilution) were incubated for 30 min with constant mixing in protein array block-
ing buffer (Whatman, Florham Park, NJ) that was supplemented with a lysate of
E. coli at a final protein concentration 5 mg/ml (7). The arrays were rehydrated
in blocking buffer for 30 min, incubated with the pretreated sera for 12 h at 4°C
with constant agitation, washed in 10 mM Tris (pH 8.0)–150 mM NaCl contain-
ing 0.05% Tween 20 buffer, and then incubated with biotin-conjugated goat
anti-human IgG (Fc- fragment-specific) serum (Jackson Immunoresearch, West
Grove, PA) that was diluted 1:200 in blocking buffer. After the array slides were
washed in 10 mM Tris (pH 8.0)–150 mM NaCl, bound antibodies were detected
with streptavidin conjugated with the dye PBXL-3 (Martek, Columbia, MD). The
washed and air-dried slides were scanned with a Perkin-Elmer ScanArray Ex-
press HT apparatus at a wavelength of 670 nm and with an output of RGB
format TIFF files that were quantitated by using ProScanArray Express software
(Perkin-Elmer, Waltham, MA) with correction for spot-specific background.
Cloning and expression of recombinant proteins. ORFs corresponding to C.
burnetii immunoreactive proteins were amplified by PCR and cloned into the
pBAD/TOPO ThioFusion expression vector (Invitrogen). Recombinant proteins
were expressed as His6-tagged fusion proteins in E. coli Top10 and purified by
nickel affinity chromatography (Invitrogen).
Production of C. burnetii soluble antigen. A bead-beaten solubilized fraction of
C. burnetii termed CBUSF was prepared as a positive control antigen. Briefly,
formaldehyde-inactivated C. burnetii bacteria were frozen in liquid nitrogen for
1 min, thawed at 37°C for 1 min, and then disrupted by using FastProtein Blue
Matrix in a FastPrep instrument (Q-Biogene, Irvine, CA) according to the
manufacturer’s instructions. This cycle was repeated three times. The final pellet
was resuspended at 2% (wt/vol) in N-lauroylsarcosine (Sigma, St. Louis, MO) in
distilled H2O and mixed for 1 h. The supernatant was collected by centrifugation
at 13,000 g for 5 min and then dialyzed against distilled H2O. The final product
was quantified by using a Micro-BCA protein assay kit (Pierce).
FIG. 1. Schematic of TAP product synthesis. C. burnetii Nine Mile ORFs were amplified in a first round of PCR using genomic DNA as a
template and PCR primers consisting of gene-specific sequence and common 5 overlap regions. TAP products were generated by an two additional
rounds of PCR. Second-round primers were used that incorporate unique overlap regions onto amplicon ends to allow subsequent annealing of
DNA fragments encoding T7 regulatory elements and a C-terminal His6 tag that were incorporated into the final TAP by a third round of PCR
using complementary primers.
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ELISA. Microplates (96 well; Fisher Scientific, Pittsburgh, PA) were coated
overnight at 4°C with 100 l of a 2-g/ml antigen solution. Plates were then
blocked with 200 l of 0.5% nonfat milk for 2 h at 37°C. Then, 50 l of a 1:50
dilution of human serum was added to each well, and the plates were incubated
for 1 h at 37°C. Plates were washed three times with PBST, and then 100 l of
a 1:5,000 dilution of biotin-labeled goat anti-human IgG gamma chain-specific
antibody (Sigma) was added to each well. Plates were incubated for 1 h at 37°C,
wells were washed three times with PBST, and then 100 l of ABC solution from
a Vectastain Elite PK-6100 kit (Vector Laboratories, Inc., Burlingame, CA) was
added to each well. After a 1-h incubation at room temperature, the plates were
washed with PBST, and the peroxidase activity was detected with o-phenylene-
diamine dihydrochloride (Sigma). Substrate reactions were developed for 15 min
and then stopped with 100 l of 1 M H2SO4. Reactions were measured at 490 nm
by using a Spectra Max M2 (Molecular Devices, Sunnyvale, CA), and data were
analyzed by GraphPad Prism (San Diego, CA). A positive cutoff for a given
antigen was defined as the mean absorbance of IFA-negative samples plus two
standard deviations. The percent sensitivity for a given antigen was calculated as
the number of ELISA-positive sera from the IFA-positive pool divided by the
number of IFA-positive sera. The percent specificity for a given antigen was
calculated as the number of ELISA-negative sera from the IFA-negative pool
divided by the number of IFA-negative sera.
Bioinformatics. Potentially secreted C. burnetii antigens were identified by
using a list of predicted C. burnetii secreted proteins compiled by the PathoSys-
tems Resource Integration Center (PATRIC) (http://patric.vbi.vt.edu/special
_projects/?amode	view&spId	8). The subcellular location of immunogenic
proteins was predicted by using PSORTb.
RESULTS AND DISCUSSION
Synthesis and characterization of TAP products. A total of
1,988 ORFs representing 97.2% of C. burnetii’s 2,046 coding
sequences were successfully amplified into TAP products (Fig.
1). Protein was synthesized from TAP products by IVTT and
dot blots performed to ascertain the number of reactions that
produced full-length recombinant protein. Based on a positive
reaction between the Penta-His monoclonal antibody and the
FIG. 2. Protein microarray analysis of the human humoral response to C. burnetii infection or vaccination. Microarrays were probed with paired
“early” and “late” acute Q fever patient sera that was obtained at 20 and 96 days, respectively, after the onset of clinical Q fever (left panels) or
in duplicate with serum from a human Q-Vax vaccinee (right panels). A laser confocal scanner was used to visualize reactive proteins with bound
PBXL-3-conjugated streptavidin. Proteins within boxes are recognized by both Q fever patient and vaccinee sera. Proteins within circles are
differentially recognized by Q fever patient and vaccinee sera. Proteins within hexagons and triangles are differentially recognized by early and late
Q fever patient sera, respectively.
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C-terminal His6 tag, full-length recombinant protein was pro-
duced from 1,492 TAP products representing 72.9% of the
predicted C. burnetii proteome (data not shown). Based on
signal intensities, there was obvious variation in the amount of
protein produced by IVTT from individual TAP products.
There were deficiencies in the production of the previously
described C. burnetii antigens Hsp60 (CBU1718) (32), which
was not amplified, and Com1 (CBU1910) (12), which was
amplified into a TAP product but poorly expressed by IVTT.
Immunoproteome characterization by protein microarray.
Protein microarrays were generated by spotting His6 tag-pos-
itive and -negative IVTT reactions onto nitrocellulose-coated
glass slides. Antigen-specific antibody responses to C. burnetii
infection or vaccination were then assessed by individually
probing microarrays with sera derived from five Q-Vax vacci-
nees, five Q fever patients (both early and late serum samples),
and six naive individuals.
Representative fluorescence signals of probed microarrays
are depicted in Fig. 2. Arrays probed with naive serum showed
few immunoreactive proteins (data not shown). Conversely,
arrays probed with early (20 days after the onset of clinical
symptoms) and late (96 days after the onset of clinical symp-
toms) acute Q fever serum showed multiple immunoreactive
proteins with stronger signal intensities for individual proteins
generally associated with arrays probed with late immune sera.
A subset of proteins was selectively recognized by early or late
sera. Temporal development of antigen-specific antibody re-
sponses has been previously described in a guinea pig model of
Q fever (6). Early antigens would likely be optimal as Q fever
serodiagnostic antigens, while late antigens, with their more
prominent role in development of protective immunity, may
prove more efficacious in subunit vaccines. Although there was
obvious overlap between proteins recognized by Q fever con-
valescent and Q-Vax vaccinee sera, each serum type also rec-
ognized a unique subset of proteins. Proteins selectively rec-
ognized by patient sera may represent secreted proteins that
are present at low levels in killed whole-cell vaccine prepara-
tions (discussed in more detail below). Arrays probed in du-
plicate showed nearly identical fluorescence patterns, demon-
strating the reproducibility of the microarray procedure. Some
immunoreactive proteins were His tag negative, indicating
IVTT can incompletely synthesize proteins to result in C-ter-
minal truncations (data not shown).
Comparison of TAP product and plasmid-based arrays. Re-
sults in our laboratory suggested that protein is more efficiently
synthesized by IVTT from expression plasmids than from TAP
fragments. Therefore, to directly compare the two methods, we
cloned ORFs encoding the 44 most immunoreactive proteins
identified above from the TAP product proteome array into a
T7 expression plasmid. Proteins were then generated by IVTT
from both plasmid and TAP templates and printed as single
replicates onto smaller arrays. Arrays were then probed with 9
sera from acute Q fever patients (including two pairs of early
and late sera), two Q-Vax vaccinee sera, and 16 naive sera. As
depicted in Fig. 3 and detailed in Table 1, patient and vaccinee
sera generally recognized the same proteins on plasmid- and
FIG. 3. Fluorescence intensity plots of plasmid- and TAP fragment-based protein microarrays probed with human sera. Plasmid- and TAP
fragment-based protein microarrays were probed individually with sera from two Q-Vax vaccinees (V1 and V2) and seven acute Q fever patients
(P1 to P7) that included paired early (E) and late (L) serum from patients 1 and 2. Arrays were also probed with sera from 16 C. burnetii-naive
individuals (N). The average fluorescence intensity values were determined for each protein, with the intensity plot showing the most reactive
proteins in red. Proteins are ordered from top (most reactive) to bottom (least reactive) according to the fluorescence intensity values of
plasmid-based arrays. Four representative intensity plots of plasmid-based arrays probed with naive serum samples are shown, while only the
intensity plots of TAP-fragment-based arrays probed with patient sera are shown.
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TAP fragment-based arrays. However, the fluorescence inten-
sity of individual proteins was generally greater on plasmid-
based arrays, indicating more efficient IVTT protein produc-
tion from plasmid templates.
Features of immunoreactive proteins. Thirteen of the forty-
four immunogenic proteins are annotated as hypothetical
proteins (22) (Table 1). Based on predicted signal peptides, 9
immunoreactive proteins among the top 44 (20.5%) were pre-
dicted to be secreted into the periplasm or beyond. Eight of
these proteins were among the top fifteen (53.3%), a finding
which contrasts markedly with the percentage of predicted
secreted proteins within the entire proteome (10.2%). A sim-
ilar bias in signal sequence-containing proteins was observed in
a proteome microarray screen of F. tularensis antigens (10, 25).
In addition to a type II secretory pathway, C. burnetii encodes
a Dot/Icm type IV secretion system that translocates effector
molecules into the host cell cytosol (19). Immunoreactive
CBU0781 (AnkG), an ankyrin repeat domain-containing pro-
TABLE 1. Forty-four immunoreactive C. burnetii proteins identified by protein microarraya
ORF no. Protein function ORFname
Signal
peptideb
Predicted subcellular
locationc
Avg array signal intensityd
Plasmid TAP
P V N P V N
CBU0891 Hypothetical exported membrane-associated
protein
 Unknown 35,248 3,618 124 12,752 111 –
CBU0612 Outer membrane protein OmpH ompH  Outer membrane 24,825 20,955 2,881 9,277 3,540 762
CBU1143 Preprotein translocase, YajC subunit yajC  Noncytoplasmic 23,756 3,222 665 9,927 521 10
CBU1398 2-Oxoglutarate dehydrogenase sucB Cytoplasmic 21,849 –e 224 11,471 – 31
CBU0545 LemA protein lemA Unknown 15,922 4,348 248 7,689 1,393 –
CBU1853 GtrA family protein Cytoplasmic membrane 15,594 14,574 563 6,644 6,529 443
CBU0754 Efflux transporter, RND family, MFP
subunit
 Cytoplasmic membrane 13,898 8,861 297 374 – –
CBU2065 Hypothetical exported protein Cytoplasmic membrane 13,577 15,646 440 1,276 – 35
CBU0307 OmpA-like transmembrane domain protein  Outer membrane 12,930 5,479 60 643 219 –
CBU1869 Hypothetical exported protein  Noncytoplasmic 12,281 15,781 778 2,309 342 247
CBU1967 Drug resistance transporter, Bcr/CflA family  Cytoplasmic membrane 10,013 6,071 46 812 322 –
CBU0968 Phospholipase D  Cytoplasmic membrane 9,850 634 265 1,213 1,360 18
CBU1115 Hypothetical protein Unknown 9,085 10,329 498 3,435 5,584 227
CBU1835 Protoporphyrinogen oxidase Cytoplasmic 8,558 427 28 1,148 – –
CBU0664 Transposase, ISAs1 family Cytoplasmic 8,422 3,334 712 740 – 73
CBU1184 Acyltransferase family protein Unknown 7,432 2,943 49 296 495 –
CBU0718 Hypothetical membrane-associated protein Unknown 6,335 – 199 3,461 – –
CBU0935 RNA-binding protein  Unknown 5,997 3,258 304 3,619 1,182 311
CBU1940 ATP synthase F0, C subunit Cytoplasmic membrane 4,539 3,128 401 1,931 1,364 76
CBU0609 Mevalonate kinase Unknown 4,234 1,206 73 54 793 –
CBU0781 Ankyrin repeat protein ankG Secreted 4,186 – 420 561 152 52
CBU1249 DNA-binding protein Unknown 4,017 467 324 5,260 1,002 95
CBU0898 Thyroglobulin type 1 repeat domain protein Unknown 3,914 3,834 135 2,427 900 58
CBU1865 Hypothetical membrane-associated protein Cytoplasmic membrane 3,225 758 246 688 444 85
CBU1098 Hypothetical cytosolic protein Cytoplasmic 3,142 4,049 71 2,468 9,747 19
CBU0774 Stress-responsive transcriptional regulator
PspC
pspC Unknown 2,983 835 335 2,984 2,145 237
CBU0800 Hypothetical protein Unknown 1,817 1,064 31 1,051 945 27
CBU0383 DNA-3-methyladenine glycosidase I tag Unknown 1,790 3,220 58 285 – 152
CBU1966 Glutamyl-tRNA reductase hemA Cytoplasmic 1,624 – 172 23 – –
CBU1697 Endonuclease III nth Unknown 1,620 1,961 22 669 – 72
CBU0776 ABC transporter, ATP-binding protein Cytoplasmic membrane 1,448 – 94 2 – 9
CBU1002 Biotin operon repressor/biotin synthetase birA Unknown 1,254 – 8 3 163 –
CBU1958 Hypothetical ATPase Unknown 1,248 3,259 119 394 225 46
CBU0366 Phosphate regulon sensor protein PhoR phoR Cytoplasmic membrane 1,010 – 456 944 1,009 400
CBU1969 DnaK suppressor protein dksA Cytoplasmic 1,007 765 81 793 1,732 26
CBU2020 Glutamate/gamma-aminobutyrate antiporter Cytoplasmic membrane 1,004 601 – 78 – 57
CBU0760 Sensor protein GacS Unknown 749 1,423 37 1,036 640 23
CBU0723 Hypothetical protein Unknown 704 2,520 126 683 920 172
CBU1121 Hypothetical protein Unknown 672 1,724 79 1,295 778 90
CBU1157 Hypothetical exported lipoprotein Unknown 522 – 26 21 – 23
CBU0008 Hypothetical protein Unknown 513 2,408 109 494 1,377 89
CBU0098 Nicotinate-nucleotide pyrophosphorylase nadC Cytoplasmic 468 – 11 504 1,010 5
CBU0391 Riboflavin biosynthesis protein RibF ribF Cytoplasmic 453 – 6 96 588 22
CBU1065 2-5 RNA ligase Cytoplasmic 158 323 45 643 726 2
a Immunoreactive proteins ordered from top (most reactive) to bottom (least reactive) based on average fluorescence intensity values of plasmid-based arrays probed
Q fever patient sera.
b Predicted signal peptide as determined by SignalP.
c Predicted subcellular location as determined by Psort.
d P, Q fever patient sera; V, Q-Vax vaccinee sera; N, naive sera.
e –, signal absent with all sera.
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tein, has been recently shown to be secreted in a Dot/Icm-
dependent manner (19). Secreted immunogens that disassoci-
ate with C. burnetii are likely present in very low amounts in the
Q-Vax vaccine. Consistent with this idea, AnkG’s patient to
vaccinee average fluorescence array signal ratio was 489 to 1.
This contrasts with a ratio of 2.1 to 1 for the most reactive
protein CBU0891, a hypothetical membrane associated pro-
tein (Table 1).
A few C. burnetii antigens have been identified by immuno-
screening a phage expression library (32) and proteins sepa-
rated by two-dimensional gel electrophoresis (6). Among the
16 proteins showing the strongest average fluorescence signals
by microarray, CBU0891, CBU1398 (2-oxglutarate dehydroge-
nase, SucB), and CBU0664 (ISAs1 family transposase) were
previously identified as immunogens by Zhang et al. (32), in-
dicating reproducibility between microarray and conventional
antigen screening procedures. Antibody recognition of SucB
indicates cytosolic housekeeping enzymes are exposed to the
host’s immune system. Indeed, in this report and elsewhere (6,
32), additional C. burnetii housekeeping enzymes, such as iso-
leucyl-tRNA synthetase and isocitrate dehydrogenase, have
been identified in antigen screens. Moreover, metabolic en-
zymes of other bacterial pathogens are known to trigger B-cell
responses (26, 30).
ELISA validation of protein microarray data. To validate
protein microarray results using another serological method,
10 reactive proteins showing a range of average fluorescence
intensities were purified as recombinant His6-tagged protein
and tested by ELISA. The 10 proteins chosen for testing were:
CBU0008 (hypothetical protein), CBU0381 (DNA-3-methyl-
adenine glycosidase), CBU0612 (outer membrane protein
OmpH), CBU0781 (AnkG), CBU1115 (hypothetical protein),
CBU1143 (preprotein translocase YajC), CBU1157 (hypothet-
ical exported lipoprotein) CBU1249 (putative DNA-binding
protein), CBU1853 (GtrA family protein), and CBU1869 (hy-
pothetical exported protein). CBU0891 was not tested because
of difficulty in obtaining recombinant protein. Recombinant
His6-tagged Com1 (CBU1910), a characterized C. burnetii pro-
tein antigen (12), and C. burnetii cell extracts (CBUSF), were
included as positive controls. As negative controls, recombi-
nant IcmE and IcmK, two array-negative proteins that are part
of the organism’s type IV secretion system (29), were included.
ELISA was conducted using 55 and 5 serum samples from
human acute and chronic Q fever patients, respectively, that
tested positive for C. burnetii antibodies by immunofluores-
cence assay (see Materials and Methods). ELISA was also
conducted using 32 IFA-negative human sera, including the 16
naive sera used in microarray screens. Seven of ten recombi-
nant proteins were positive by ELISA when tested with sera
from acute Q fever patients. When tested with sera from en-
docarditis patients, all recombinant proteins were positive
(Fig. 4 and Table 2). Consistent with microarray results, the
negative control proteins IcmE and IcmK were negative by
ELISA. We did not observe a clear correlation between IFA
titer and responses by ELISA to specific recombinant proteins.
However, convalescent human sera with high IFA titers con-
sistently demonstrated positive reactivity against all recombi-
nant proteins, whereas several convalescent-phase sera with
low IFA titers did not react strongly with any recombinant
protein (data not shown). Sensitivity and specificity for the 10
recombinant proteins ranged from 31.6 to 61.6% to 78.1 to
90.0%, respectively. CBUSF gave the highest sensitivity at
85%. While none of the individual recombinant proteins pro-
vided complete coverage for IFA-positive samples, six out ten
proteins showed greater sensitivities than the positive control
CBU1910 (Com1). Combining several recombinant proteins
FIG. 4. ELISA validation of immunogenic proteins identified by microarray. Recombinant proteins corresponding to 10 antigens identified by
protein microarray were generated and tested by ELISA for IgG reactivity of human sera. A sampling of proteins that ranged from strongly (e.g.,
CBU1143) to weakly (e.g., CBU0008) reactive were tested. Recombinant Com1 (CBU1910), a characterized C. burnetii protein antigen, was
included as a positive control. Recombinant IcmE and IcmK, which tested negative by protein microarray, were included as controls. ELISA was
conducted on 55 and 5 serum samples from human acute (gray triangles) and chronic Q fever patients (boxes), respectively, that tested positive
for C. burnetii antibodies by indirect immunofluorescence assay (see Materials and Methods). ELISA was also conducted on 32 IFA-negative sera
(black triangles). Black lines denote the mean reactivity of positive and negative sera. Dashed black lines denote the positive cutoff, which was
calculated as the mean ELISA reactivity of IFA-negative sera samples plus two times the standard deviation. CBUSF, C. burnetii soluble fraction.
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significantly increased sensitivity but also moderately reduced
specificity (data not shown). While a final recombinant protein
mixture equal to or superior to CBUSF was not defined, these
studies did support the concept that a limited multiplex assay
can be developed to replace whole-cell reagents in a new Q
fever diagnostic.
While the primary goal of the present study was to identify
C. burnetii proteins with serodiagnostic potential, some of the
identified immunogens may be candidates for a Q fever sub-
unit vaccine. Both cell-mediated and humoral immune re-
sponses are important for protection against Q fever (33), and
accumulating evidence suggests that an efficacious vaccine
based on recombinant antigen is feasible (27, 31, 34). Indeed,
several purified proteins including CBU0781 (AnkG),
CBU1157 (lipoprotein), and CBU1143 (YajC) induce strong
gamma interferon recall responses in purified CD4 T cells of
vaccinated or infected mice (J. E. Samuel, unpublished data).
Interestingly, YajC, an inner membrane protein involved in
Sec-dependent secretion (9), is both a B-cell and a T-cell
antigen of Brucella abortus (28). Testing of microarray-identi-
fied antigens for T-cell antigenicity does not require purified
recombinant protein as IVTT-produced antigen, either cou-
pled to latex beads by an affinity tag or contained within in
crude IVTT lysates, both effectively stimulate T cells in prolif-
eration assays (13, 14).
In summary, we have used a high-throughout proteome mi-
croarray screening method to identify C. burnetii proteins rec-
ognized by the human humoral immune response to C. burnetii
infection and vaccination. This screening method allows pro-
filing of antibody responses of large cohorts of infected and/or
vaccinated animals and humans to rapidly identify consensus
immunodominant antigens on a whole-proteome basis. Iden-
tification of immunodominant antigens of C. burnetii will aid in
the development of safe and effective recombinant protein-
based vaccines and reliable serodiagnostic tests that do not
require biosafety level 3 facilities for antigen production. We
are currently developing a second-generation C. burnetii
IVTT-based microarray that includes proteins unique to two
chronic Q fever endocarditis isolates (G and K) (3). Compar-
isons of the immunoproteome of acute and chronic disease
isolates may identify unique serodiagnostic antigens that allow
differentiation of acute and chronic Q fever.
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